Hence, CD36 palmitoylation appears crucial in the pathogenesis of NASH, and inhibiting CD36 palmitoylation might represent a significant therapeutic strategy for treating NASH. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatohepatitis.